FDA Mock Inspections: Types, Common Findings and How to Prepare

Not every FDA mock inspection looks the same. The discipline a regulator will scrutinize, and the questions your team needs to answer, depend on where your product sits in its development journey. A clinical-stage biotech preparing for a BIMO mock inspection faces very different challenges from a commercial manufacturer rehearsing a GMP inspection. Choosing the right type of rehearsal is the first step to getting real value from it.

This article walks through the main types of mock inspection, mapped to the stages of drug development: GCP and BIMO at the clinical stage, GVP for pharmacovigilance, and GMP for manufacturing and commercial supply. For each, we cover what the FDA and other regulators look for, and the findings they cite most often.

What a mock inspection is

Whatever the discipline, a mock inspection is a realistic simulation of a regulatory visit, run by senior auditors before the real inspector arrives. A consultant takes the role of the investigator, requesting documents, touring the facility where relevant, and interviewing your subject matter experts exactly as an inspector would. It surfaces the practical issues that catch teams out: how quickly you retrieve a record, how the front room communicates with the back room, and whether staff answer questions clearly under pressure. Apotech’s mock inspection services mirror exactly how the FDA, EMA, and other global health authorities work. What changes from one mock inspection to the next is scope, and that depends on your stage of development.

Match the mock inspection to your stage of development

As a product moves from the laboratory to the clinic to the market, the GxP discipline under examination shifts with it. The three rehearsals below cover the journey most pharma and biotech companies will travel.

Clinical stage: GCP and BIMO mock inspections

For companies running clinical trials, the FDA’s Bioresearch Monitoring (BIMO) program is the main event. BIMO inspections examine clinical investigators, sponsors, CROs, and institutional review boards to confirm that trial data is reliable and that subjects were properly protected. The agency conducted more than 1,000 BIMO inspections in FY2023, the majority focused on these parties.

A BIMO mock inspection rehearses this scrutiny against Good Clinical Practice (GCP). The findings the FDA cites most often will be familiar to anyone who has run a trial:

• Failure to follow the investigational plan or protocol.
• Inadequate sponsor oversight and trial monitoring.
• Informed consent and subject protection deficiencies.
• Investigational product accountability errors.
• Recordkeeping and data integrity gaps in the trial master file.

Because so much rests on documentation, a strong rehearsal tests records against ALCOA-C principles: attributable, legible, contemporaneous, original, accurate, and complete. This work sits naturally alongside a GCP audit. Earlier still, preclinical safety studies fall under Good Laboratory Practice (GLP), which carries its own inspection expectations and is best tested through a focused GLP audit.

Pharmacovigilance: GVP mock inspections

Pharmacovigilance obligations begin during clinical development and intensify once a product reaches the market, which makes Good Pharmacovigilance Practice (GVP) a discipline in its own right. In Europe, National authorities like ANSM in France or MHRA in the UK run dedicated GVP inspections, and the FDA scrutinizes post-marketing safety reporting through its own programs. A GVP mock inspection checks that your safety system can withstand examination, looking at:

• The accuracy and currency of your pharmacovigilance system master file (PSMF).
• Oversight by the qualified person responsible for pharmacovigilance (QPPV), and clarity of the role.
• Individual case safety report (ICSR) handling and expedited reporting timelines.
• Signal detection, evaluation, and management.
• Aggregate reports such as the PSUR or PBRER, and the actions taken from them.

Safety findings, like any other, should drive corrective action that holds up under follow-up. A GVP audit examines the same system on a planned, scheduled basis and is a sensible complement to a mock inspection.

Manufacturing and commercial supply: GMP mock inspections

As a product approaches approval, manufacturing comes under the microscope through a pre-approval inspection (PAI), followed by routine surveillance once you are commercial. A GMP mock inspection rehearses this. FDA findings here are remarkably consistent year to year:

• Quality unit failures. Failure to follow written quality unit procedures (21 CFR 211.22(d)) was the single most cited drug observation in FY2024, and it has held the top spot for four years running.
• Data integrity. Incomplete, missing, or altered records, weak access controls, and laboratory data that cannot be traced.
• Inadequate written procedures. Either no procedure exists, or staff do not follow the one that does.
• Incomplete investigations and CAPA. Investigations that never reach root cause, and corrective actions that do not demonstrably fix the problem.
• Training, equipment, and validation gaps. Insufficient GMP training, poorly maintained equipment, and missing process validation, especially for sterile products.

The FDA’s reach is global: more than 60% of drug quality inspections in FY2024 took place at facilities outside the United States, so the same expectations apply whether your site is in New Jersey or Mumbai. Most of these findings trace back to the fundamentals in our guide to GxP best practice, and many surface first during a GMP and GDP audit or a focused data integrity review.

Common findings across FDA inspections

The disciplines differ, but a handful of themes recur across almost every Form 483, whatever the inspection type. They are worth knowing because they are exactly what a mock inspection is built to catch, and the issues most likely to escalate if they slip through:

• Data integrity. The same expectation applies from the lab bench to the trial master file to the safety database: records must be attributable, complete, and impossible to alter without trace.
• Procedures that are missing or ignored. Either no written procedure exists, the one in place is out of date, or staff simply do not follow it.
• Weak investigations and CAPA. Investigations that stop short of root cause, and corrective actions that are never verified for effectiveness.
• Insufficient oversight. A quality unit, sponsor, or QPPV that does not visibly exercise its authority, leaving gaps that no one owns.
• Training gaps. People carrying out tasks they have not been trained to perform, or with no record to show that they were.

The pattern is clear: the FDA rarely finds something genuinely new. It finds the same fundamentals left unaddressed. That is good news, because it means a focused rehearsal can close most of these gaps before they ever reach a real inspector.

Turn a mock inspection into permanent readiness

Whichever type you run, the point of a mock inspection is not to pass a test once. It is to build an organization that is ready at any time. A well-run program works through a few clear stages.

It starts with a readiness review to map your current gaps, often delivered as part of broader quality assurance support. From there, the simulation puts your systems and people under realistic pressure, with the scope tailored to your product and risk level. Interview coaching is a critical and often overlooked element, because the way an SME answers a question can matter as much as the underlying data. Finally, any findings feed into a structured remediation plan rather than a one-off fix, ideally through a genuine CAPA process with verified effectiveness checks, so the same observation does not reappear when the real inspector arrives.

Prepare with Apotech

The findings the FDA cites are predictable, which means readiness is achievable. The key is matching the rehearsal to your stage, whether that is a clinical-stage FDA BIMO mock inspection, a GVP review of your safety system, or a full GMP simulation ahead of commercial supply.

Apotech runs ex-FDA led mock inspections for pharma, biotech, and medical device teams across more than 100 countries, modeled on how the FDA, EMA, and MHRA actually work. To prepare for your next inspection, speak with our team.